Abstract: The present invention relates to sigma-2 receptor agonists and their use in the treatment of immunodeficiency virus infections, especially human immunodeficiency virus (HIV) infections. The invention particularly relates to sigma-2 agonists, especially CB-184 and its analogues, that decrease cellular production of sphingomyelin when provided to recipient cells, and inhibit HIV replication.
Type:
Application
Filed:
July 15, 2005
Publication date:
January 5, 2006
Applicant:
The United States of America, per Secy. DHHS, NIH
Inventors:
Wayne Bowen, Keith Crawford, James Hildreth